Ulrich T Hacker
Overview
Explore the profile of Ulrich T Hacker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Catanese S, Beuchel C, Sawall T, Lordick F, Brauer R, Scholz M, et al.
J Cachexia Sarcopenia Muscle
. 2021 Oct;
12(6):2101-2110.
PMID: 34636159
Background: Cachexia is characterized by a negative protein and energy balance leading to loss of adipose tissue and muscle mass. Cancer cachexia negatively impacts treatment tolerability and prognosis. Supportive interventions...
12.
Scarpitta A, Hacker U, Buning H, Boyer O, Adriouch S
Front Oncol
. 2021 Sep;
11:731598.
PMID: 34490126
Cancer remains the second most common cause of death worldwide affecting around 10 million patients every year. Among the therapeutic options, chemotherapeutic drugs are widely used but often associated with...
13.
Hacker U, Bentler M, Kaniowska D, Morgan M, Buning H
Cancers (Basel)
. 2020 Jul;
12(7).
PMID: 32674264
Adeno-associated virus (AAV) vectors have gained tremendous attention as in vivo delivery systems in gene therapy for inherited monogenetic diseases. First market approvals, excellent safety data, availability of large-scale production...
14.
Westphalen B, Bokemeyer C, Buttner R, Frohling S, Gaidzik V, Glimm H, et al.
Eur J Cancer
. 2020 Jun;
135:1-7.
PMID: 32521293
Precision cancer medicine (PCM) holds great promises to offer more effective therapies to patients based on molecular profiling of their individual tumours. Although the PCM approach seems intuitive, multiple conceptional...
15.
Hacker U, Hasenclever D, Linder N, Stocker G, Chung H, Kang Y, et al.
J Cachexia Sarcopenia Muscle
. 2019 Aug;
11(1):135-144.
PMID: 31464089
Background: Body fat and/or muscle composition influences prognosis in several cancer types. For advanced gastric and gastroesophageal junction cancer, we investigated which body composition parameters carry prognostic information beyond well-established...
16.
Stocker G, Hacker U, Fiteni F, John Mahachie J, Roth A, Van Cutsem E, et al.
Eur J Cancer
. 2018 Jun;
99:49-57.
PMID: 29906734
Background: Dose reduction in obese cancer patients has been replaced by fully weight-based dosing recommendations. No data, however, are available on the effects of dose reduction in obese stage III...
17.
Hosel M, Huber A, Bohlen S, Lucifora J, Ronzitti G, Puzzo F, et al.
Hepatology
. 2017 Mar;
66(1):252-265.
PMID: 28318036
Conclusion: We identified autophagy as a pivotal cell response determining the efficiency of AAVs intracellular processing in hepatocytes and thus the outcome of liver-directed gene therapy using AAV vectors and...
18.
Adeno-Associated Viral Vectors Transduce Mature Human Adipocytes in Three-Dimensional Slice Cultures
Kallendrusch S, Schopow N, Stadler S, Buning H, Hacker U
Hum Gene Ther Methods
. 2016 Sep;
27(5):171-173.
PMID: 27650213
Adipose tissue plays a pivotal role, both in the regulation of energy homeostasis and as an endocrine organ. Consequently, adipose tissue dysfunction is closely related to insulin resistance, morbid obesity,...
19.
Hacker U, Escalona-Espinosa L, Consalvo N, Goede V, Schiffmann L, Scherer S, et al.
Br J Cancer
. 2016 Apr;
114(8):855-62.
PMID: 27031850
Background: In the phase III AVAGAST trial, the addition of bevacizumab to chemotherapy improved progression-free survival (PFS) but not overall survival (OS) in patients with advanced gastric cancer. We studied...
20.
Weihrauch M, Richly H, von Bergwelt-Baildon M, Becker H, Schmidt M, Hacker U, et al.
Eur J Cancer
. 2014 Dec;
51(2):146-56.
PMID: 25480557
Purpose: This study was initiated to evaluate safety, toxicity, pharmacokinetics, and pharmacodynamics of treatment with MGN1703, a novel synthetic DNA-based toll-like receptor 9 (TLR9)-immunomodulator. Methods: The study consisted of an...